Showing 2039 results
-
Press release /Approvals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im dritten Quartal um +4% kWk1 (–4% USD): Innovative Medicines (IM) steigerte den Umsatz um +4% kWk (–3% USD), getragen von…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Die strategische Überprüfung von Sandoz hat ergeben, dass eine Abspaltung von Sandoz durch eine hundertprozentige Ausgliederung im besten Interesse…
-
Story /Global Oncology Patient Insights Panels (GOPIPs) are giving patients and advocates a critical voice in advancing lung cancer trials.
-
Story /Our Chief Learning Officer, Simon Brown, talks about our ongoing efforts to build new capabilities by investing in our own people.
-
Press release /Sandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] …
-
Pulse Update /
-
Pulse Update /
-
Press release /Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products;…
-
Clinical Trials /